The FDA has approved Trelegy Ellipta (GSK, Innoviva) single-inhaler triple chronic obstructive pulmonary disease (COPD) therapy.
Indications: Trelegy Ellipta (fluticascone/furoate/umeclidinium/vilanterol) is indicted for the long-term, once-daily, maintenance treatment of certain patients with COPD, including chronic bronchitis or emphysema, who are on the fixed-dose combination of fluticasone furoate and vilanterol for airflow obstruction and reducing exacerbations in whom additional treatment of airflow obstruction is desired or for patients who are already receiving umeclidinium and a fixed-dose combination of fluticasone furoate and vilanterol.
Dosage/administration: 1 inhalation once daily as maintenance treatment of COPD.
Adverse reactions: The most common adverse reactions (incidence ≥1%) are headache, back pain, dysgeusia, cough, oropharyngeal pain, and gastroenteritis.
Trelegy Ellipta approved as the first once-daily single inhaler triple therapy for the treatment of appropriate patients with COPD in the US. [news release]. GlaxoSmithKline: London, UK. http://us.gsk.com/en-us/media/press-releases/2017/trelegy-ellipta-approv.... Accessed September 18, 2017.
Must Reads in FDA Actions
FDA Approves Steglatro for Adults with T2D, Pfizer news release; 2017 Dec 22
FDA Approves Ozempic for Treatment of T2D, Novo Nordisk news release; 2017 Dec 5
FDA Approves Epinephrine Autoinjector for Infants, Kaléo news release; 2017 Nov 20
FDA Approves Fasenra for Severe Eosinophilic Asthma, AstraZeneca news release; 2017 Nov 14
Shingrix Approved for Prevention of Shingles, GSK news release; 2017 Oct 23